Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\30035121
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Biomed+Res+Int
2018 ; 2018
(ä): 3606970
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Primary CNS Lymphomas: Challenges in Diagnosis and Monitoring
#MMPMID30035121
Chiavazza C
; Pellerino A
; Ferrio F
; Cistaro A
; Soffietti R
; Rudà R
Biomed Res Int
2018[]; 2018
(ä): 3606970
PMID30035121
show ga
Primary Central Nervous System Lymphoma (PCNSL) is a rare neoplasm that can
involve brain, eye, leptomeninges, and rarely spinal cord. PCNSL lesions most
typically enhance homogeneously on T1-weighted magnetic resonance imaging (MRI)
and appear T2-hypointense, but high variability in MRI features is commonly
encountered. Neurological symptoms and MRI findings may mimic high grade gliomas
(HGGs), tumefactive demyelinating lesions (TDLs), or infectious and granulomatous
diseases. Advanced MRI techniques (MR diffusion, spectroscopy, and perfusion) and
metabolic imaging, such as Fluorodeoxyglucose Positron Emission Tomography
(FDG-PET) or amino acid PET (usually employing methionine), may be useful in
distinguishing these different entities and monitoring the disease course.
Moreover, emerging data suggest a role for cerebrospinal fluid (CSF) markers in
predicting prognosis and response to treatments. In this review, we will address
the challenges in PCNSL diagnosis, assessment of response to treatments, and
evaluation of potential neurotoxicity related to chemotherapy and radiotherapy.
|*Central Nervous System Neoplasms/diagnosis/therapy
[MESH]